Last reviewed · How we verify
Pioglitazone Open Label
Pioglitazone, an open-label drug developed by the University of Florida, is currently marketed but lacks a specified primary indication or revenue data. The key strength lies in its patent protection, which extends until 2028, providing a barrier to generic competition. The primary risk is the absence of detailed clinical trial results and clear market positioning, which may limit its competitive edge.
At a glance
| Generic name | Pioglitazone Open Label |
|---|---|
| Also known as | Actos (brand name), manufactured by Takeda Pharmaceuticals. |
| Sponsor | University of Florida |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants (PHASE1)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes (PHASE3)
- A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes (PHASE4)
- A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed) (PHASE1)
- A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting) (PHASE1)
- A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone Open Label CI brief — competitive landscape report
- Pioglitazone Open Label updates RSS · CI watch RSS
- University of Florida portfolio CI